GW Pharma Brings to Market First Cannabidiol Medication for Treating Rare Epilepsy Disorders

GW Pharmaceuticals is the first company to bring a cannabis plant-based drug to market to treat rare forms of epilepsy. Epidiolex ® (cannabidiol or CBD) was cleared by the FDA in June 2018 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. The drug received a Fast Track designation by the FDA due to its great potential shown in successful trials with children and because at the time there were no other drugs to treat Dravet syndrome effectively. CBD has also been rescheduled as a Schedule V drug.
https://www.federalregister.gov/documents/2018/09/28/2018-21121/schedules-of-controlled-substances-placement-in-schedule-v-of-certain-fda-approved-drugs-containing